Navellier & Associates Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bunge Global
BG
|
+$11.6M |
| 2 |
Archer Daniels Midland
ADM
|
+$9.76M |
| 3 |
Costco
COST
|
+$6.59M |
| 4 |
First Trust Health Care AlphaDEX Fund
FXH
|
+$5.6M |
| 5 |
Eli Lilly
LLY
|
+$5.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
West Pharmaceutical
WST
|
+$16.9M |
| 2 |
Johnson Controls International
JCI
|
+$10.1M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$7.93M |
| 4 |
Entegris
ENTG
|
+$7.86M |
| 5 |
Intuit
INTU
|
+$6.84M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 18.46% |
| 2 | Technology | 13.89% |
| 3 | Consumer Staples | 13.84% |
| 4 | Industrials | 12.91% |
| 5 | Materials | 10.93% |
Similar funds
Navellier & Associates's Q2 2022 Portfolio in Review
As of Q2 2022, Navellier & Associates held 343 positions worth $466M, down 21% from $588M the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Navellier & Associates withdrew a net $33.7M in Q2 2022, closing 70 positions and reducing 115 holdings. Its most notable exit was West Pharmaceutical, an estimated $16.9M position sold in full.
By sector, the portfolio is most concentrated in Energy at 18% of assets, up from 11% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Navellier & Associates opened a new position in First Trust Health Care AlphaDEX Fund worth $5.36M.
- Navellier & Associates's largest Q2 2022 buy was First Trust Health Care AlphaDEX Fund: 52,000 shares worth $5.36M.
- Navellier & Associates added most to Bunge Global in Q2 2022, an estimated $11.6M increase.
- Navellier & Associates's biggest Q2 2022 reduction was AMN Healthcare, cutting an estimated $3.55M.
- Navellier & Associates fully exited West Pharmaceutical in Q2 2022, selling an estimated $16.9M.
- Navellier & Associates's ten largest holdings make up 20% of its $466M portfolio in Q2 2022.
- Navellier & Associates opened 56 new positions and closed 70 in Q2 2022.
- Navellier & Associates's portfolio value fell 21% quarter-over-quarter to $466M.
Based on Navellier & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.